Slow release formulation containing antibiotic and its uses
A technology for antibiotics and sustained-release injections, applied in the field of sustained-release preparations, sustained-release injections containing antibiotics and sustained-release implants, can solve the problems of increased dose side effects, difficulty in obtaining effective bactericidal concentrations, etc. The effect of convenient drug application and cost reduction
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0112] Put 90, 90 and 80 mg of polyphenylpropane (p-carboxyphenylpropane (p-CPP): sebacic acid (SA) at 20:80) copolymers into (A), (B) and (C) three Then add 100 milliliters of dichloromethane to each container, after dissolving and mixing, add 10 mg dafloxacin, 10 mg cephalexin, and 20 mg tylosin respectively, and prepare 10% Dafloxacin containing 10% Dafloxacin by spray drying method after re-shaking Flufloxacin, 10% cephalexin and 20% Tylosin microspheres for injection. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection. The viscosity of the injection is 300cp-600cp (at 20°C-30°C). The release time of the slow-release injection in physiological saline in vitro is 5-10 days, and the release time in mice subcutaneous is about 10-20 days.
Embodiment 2
[0114] The method step of being processed into slow-release injection is identical with embodiment 1, but difference is that contained antibacterial active ingredient and weight percentage thereof are:
[0115] (1) 2-50% apramycin, betamycin, dafloxacin, lincomycin, spectinomycin, doxycycline or streptomycin;
[0116] (2) 2-50% penicillin, difloxacin, aureomycin, carbadol, cloxacillin, marbofloxacin or pemafloxacin;
[0117] (3) 2-50% pilimycin, safloxacin, enunomycin, tylosin, cephalexin, ceftiofur or neomycin; or
[0118] (4) 2-50% salinomycin, novobiocin, ibafloxacin, gentamicin sulfate, sulfadiazine or sulfisoxazole.
Embodiment 3
[0120] Put 70 mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 10,000 into three containers (A), (B) and (C) respectively, and then add 100 ml of dichloromethane to each, dissolve and mix well , add 30mg lincomycin, 30mg doxycycline, 15mg lincomycin and 15mg doxycycline to three containers respectively, re-shake and use spray drying method to prepare 30% lincomycin, 30% doxycycline Injectable microspheres containing lincomycin, 15% lincomycin and 15% doxycycline. The dried microspheres are suspended in physiological saline containing 1.5% sodium carboxymethylcellulose to prepare the corresponding suspension-type sustained-release injection. The viscosity of the injection is 400cp-600cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 7-15 days, and the drug release time in mice subcutaneous is about 15-25 days.
PUM
Property | Measurement | Unit |
---|---|---|
glass transition temperature | aaaaa | aaaaa |
melting point | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com